Reduction in Acute Gastroenteritis Hospitalizations among US Children After Introduction of Rotavirus Vaccine: Analysis of Hospital Discharge Data from 18 US States
Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 200...
Saved in:
Published in | The Journal of infectious diseases Vol. 201; no. 11; pp. 1617 - 1624 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
The University of Chicago Press
01.06.2010
University of Chicago Press |
Subjects | |
Online Access | Get full text |
ISSN | 0022-1899 1537-6613 1537-6613 |
DOI | 10.1086/652403 |
Cover
Loading…
Abstract | Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Methods. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0–2, 3–5, 6–11, 12–17, 18–23, 24–35, 36–47, and 48–59 months), and state. Results. Compared with the median rate for the 2000–2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0–2 months had a 28% reduction, those aged 6–23 months had a reduction of 50%, and children aged 3–5 months and 24–59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000–2006 rotavirus seasons. Conclusions. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season. |
---|---|
AbstractList | In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons.
Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state.
Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons.
The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season. Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Methods. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0–2, 3–5, 6–11, 12–17, 18–23, 24–35, 36–47, and 48–59 months), and state. Results. Compared with the median rate for the 2000–2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0–2 months had a 28% reduction, those aged 6–23 months had a reduction of 50%, and children aged 3–5 months and 24–59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000–2006 rotavirus seasons. Conclusions. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season. Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons. Methods. Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state. Results. Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons. Conclusions. The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons.BACKGROUNDIn 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among US children aged <5 years during pre-RV5 rotavirus seasons from 2000 through 2006 with those during the post-RV5 2007 and 2008 seasons.Using 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state.METHODSUsing 100% hospital discharge data from 18 states, accounting for 49% of the US population, we calculated acute gastroenteritis hospitalization rates for children aged <5 years by rotavirus season, 8 age groups (0-2, 3-5, 6-11, 12-17, 18-23, 24-35, 36-47, and 48-59 months), and state.Compared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons.RESULTSCompared with the median rate for the 2000-2006 rotavirus seasons (101.1 hospitalizations per 10,000 children), the rates for 2007 and 2008 (85.5 and 55.5 hospitalizations per 10,000 children) were 16% and 45% lower, respectively. Children aged 0-2 months had a 28% reduction, those aged 6-23 months had a reduction of 50%, and children aged 3-5 months and 24-59 months had reductions ranging between 42% and 45% during the 2008 rotavirus season, compared with the median rate for 2000-2006 rotavirus seasons.The introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season.CONCLUSIONSThe introduction of the RV5 vaccine was associated with a dramatic reduction in hospitalizations for acute gastroenteritis among US children during the 2008 rotavirus season. |
Author | Hunter, Katherine Curns, Aaron T. Steiner, Claudia A. Wilson, Emily Parashar, Umesh D. Barrett, Marguerite |
Author_xml | – sequence: 1 givenname: Aaron T. surname: Curns fullname: Curns, Aaron T. email: agc8@cdc.gov organization: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 2 givenname: Claudia A. surname: Steiner fullname: Steiner, Claudia A. organization: Healthcare Cost and Utilization Project, Center for Delivery, Organization and Markets, Agency for Healthcare Research and Quality, Rockville, Maryland – sequence: 3 givenname: Marguerite surname: Barrett fullname: Barrett, Marguerite organization: M.L. Barrett, Del Mar, Santa Barbara, California – sequence: 4 givenname: Katherine surname: Hunter fullname: Hunter, Katherine organization: Thomson Reuters, Santa Barbara, California – sequence: 5 givenname: Emily surname: Wilson fullname: Wilson, Emily organization: Thomson Reuters, Santa Barbara, California – sequence: 6 givenname: Umesh D. surname: Parashar fullname: Parashar, Umesh D. organization: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20402596$$D View this record in MEDLINE/PubMed |
BookMark | eNp10c1u1DAQB3ALFdFtgTcAmQtcCPgjtjfcll3oVqpAbWmpuFgTx2ldsvFiO4jyPDwoXqVbJBAX-zC_-Xs03kM7ve8tQo8peUXJVL6WgpWE30MTKrgqpKR8B00IYayg06raRXsxXhNCSi7VA7TLSEmYqOQE_TqxzWCS8z12PZ6ZIVl8ADEFb_tkg0su4qWPa5egcz9hAyOGle8v8dkpnl-5rgk2N7YZ48M-923jfItPfILvLgwRn4Mxrrdv8KyH7ibm0Fze5uKFi-YKwqXFC0iA2-BXmE43D5wmSDY-RPdb6KJ9dHvvo7P37z7Nl8XRx4PD-eyoMKVkqVCmYYpKJRSjytRCqLKqRA2tbKkASoysIR-lKJnNLsuWGrCE1i1VdUP5Pnox5q6D_zbYmPQqT2a7Dnrrh6gV5xXnlMosn97KoV7ZRq-DW0G40dvFZvB8BCb4GINt7wglevNjevyxDF_-BU3eyWaDKYDr_uXPRu6H9f8jn4zmOiYf_sympozxkuV6MdZdTPbHXR3CVy0VV0IvL77o4-MPby8W55_1gv8GQum6Mg |
CitedBy_id | crossref_primary_10_2222_jsv_60_33 crossref_primary_10_1542_pir_33_10_439 crossref_primary_10_1093_jpids_piw020 crossref_primary_10_1016_j_vaccine_2011_07_117 crossref_primary_10_1093_cid_ciaa150 crossref_primary_10_1097_INF_0000000000000095 crossref_primary_10_1097_INF_0b013e3181fefb32 crossref_primary_10_1093_cid_ciy580 crossref_primary_10_1002_jmv_25075 crossref_primary_10_1016_j_vaccine_2016_11_056 crossref_primary_10_1016_j_vaccine_2017_05_064 crossref_primary_10_2165_11537200_000000000_00000 crossref_primary_10_1016_j_cll_2015_02_012 crossref_primary_10_1093_cid_civ1182 crossref_primary_10_1097_INF_0b013e3181fefa05 crossref_primary_10_1016_j_jcv_2012_10_016 crossref_primary_10_1016_j_vaccine_2013_08_041 crossref_primary_10_1093_infdis_jir477 crossref_primary_10_1093_infdis_jiu503 crossref_primary_10_1002_jmv_23971 crossref_primary_10_1007_s00580_011_1270_z crossref_primary_10_1097_INF_0b013e31822a8527 crossref_primary_10_1590_0102_311X00124713 crossref_primary_10_4161_hv_24846 crossref_primary_10_1016_j_vaccine_2016_08_047 crossref_primary_10_4161_hv_21577 crossref_primary_10_1155_2013_612403 crossref_primary_10_1590_0102_311X00080515 crossref_primary_10_1097_INF_0000000000001077 crossref_primary_10_3389_fpubh_2015_00269 crossref_primary_10_1016_j_vaccine_2011_07_105 crossref_primary_10_1016_j_vaccine_2016_07_001 crossref_primary_10_3389_fmicb_2020_01526 crossref_primary_10_1186_1471_2431_12_74 crossref_primary_10_1016_j_coviro_2012_05_002 crossref_primary_10_1093_infdis_jir492 crossref_primary_10_1007_s12098_014_1419_2 crossref_primary_10_1016_j_cmi_2016_03_007 crossref_primary_10_1093_jac_dkac339 crossref_primary_10_1097_INF_0b013e3181fefd78 crossref_primary_10_1038_pr_2016_95 crossref_primary_10_1093_jpids_pis058 crossref_primary_10_1097_INF_0000000000000702 crossref_primary_10_1016_j_vaccine_2016_04_014 crossref_primary_10_5144_0256_4947_2013_241 crossref_primary_10_1097_MOP_0b013e32834ee594 crossref_primary_10_1542_peds_2013_3849 crossref_primary_10_1371_journal_pone_0154340 crossref_primary_10_1586_14760584_2014_877846 crossref_primary_10_1186_1824_7288_40_14 crossref_primary_10_1038_s41598_018_19469_w crossref_primary_10_1056_NEJMoa1311738 crossref_primary_10_1016_j_meegid_2013_05_008 crossref_primary_10_1590_1982_0194201500041 crossref_primary_10_1016_j_virusres_2011_11_021 crossref_primary_10_1016_j_vaccine_2022_04_104 crossref_primary_10_1097_MCG_0000000000000907 crossref_primary_10_1111_irv_12096 crossref_primary_10_2217_imt_12_7 crossref_primary_10_1016_j_vaccine_2011_07_092 crossref_primary_10_1128_JCM_05590_11 crossref_primary_10_1177_0883073814542944 crossref_primary_10_1016_j_vaccine_2013_08_103 crossref_primary_10_1186_1471_2334_13_112 crossref_primary_10_1016_S1473_3099_11_70253_5 crossref_primary_10_1097_INF_0b013e3182254d19 crossref_primary_10_1111_j_1468_0009_2012_00664_x crossref_primary_10_1016_j_amepre_2012_10_001 crossref_primary_10_1016_j_vaccine_2011_05_017 crossref_primary_10_14776_piv_2016_23_3_202 crossref_primary_10_1016_j_meegid_2017_05_009 crossref_primary_10_1542_peds_2010_1830 crossref_primary_10_1093_cid_cit520 crossref_primary_10_1097_INF_0000000000000086 crossref_primary_10_1016_j_vaccine_2010_08_094 crossref_primary_10_1093_jpids_pix004 crossref_primary_10_1542_peds_2010_1393 crossref_primary_10_1111_j_1440_1754_2010_01953_x crossref_primary_10_1007_s11908_013_0333_5 crossref_primary_10_2478_prolas_2019_0049 crossref_primary_10_1016_j_jcv_2012_03_010 crossref_primary_10_1007_s00431_010_1245_0 crossref_primary_10_1093_cid_cis443 crossref_primary_10_1097_INF_0000000000001143 crossref_primary_10_1016_S0140_6736_10_60896_3 crossref_primary_10_4161_hv_22341 crossref_primary_10_1542_gr_27_5_49 crossref_primary_10_3346_jkms_2015_30_10_1471 crossref_primary_10_1097_MOP_0b013e32834877f1 crossref_primary_10_1590_0037_8682_0311_2014 crossref_primary_10_1155_2014_720585 crossref_primary_10_1186_1471_2458_11_462 crossref_primary_10_1016_j_cmi_2015_01_027 crossref_primary_10_1586_erv_11_184 crossref_primary_10_1016_j_ijid_2010_11_007 crossref_primary_10_1016_j_yapd_2012_04_002 crossref_primary_10_1186_1471_2334_13_54 crossref_primary_10_1007_s11606_018_4531_6 crossref_primary_10_1093_ofid_ofz115 crossref_primary_10_1016_j_vaccine_2012_11_099 crossref_primary_10_1371_journal_pmed_1001024 crossref_primary_10_1016_j_provac_2011_10_008 crossref_primary_10_3390_v7010378 crossref_primary_10_1371_journal_pntd_0003042 crossref_primary_10_1016_j_vaccine_2025_126789 crossref_primary_10_4161_hv_29386 crossref_primary_10_1080_21645515_2021_1972706 crossref_primary_10_1093_jpids_pit060 crossref_primary_10_4161_hv_7_12_18321 crossref_primary_10_1016_j_vaccine_2014_03_029 crossref_primary_10_1093_cid_civ1027 crossref_primary_10_1097_INF_0b013e31828d639c crossref_primary_10_1111_j_1440_1754_2012_02445_x crossref_primary_10_1007_s00431_013_1945_3 crossref_primary_10_1016_j_arcped_2011_07_025 crossref_primary_10_1016_S1473_3099_12_70029_4 crossref_primary_10_1093_infdis_jiw186 crossref_primary_10_1016_j_vaccine_2012_01_022 crossref_primary_10_1016_j_meegid_2014_10_013 crossref_primary_10_1016_j_vaccine_2011_10_108 crossref_primary_10_4081_jphr_2013_e9 crossref_primary_10_1097_INF_0b013e318270362c crossref_primary_10_1128_JVI_05217_11 crossref_primary_10_4161_hv_20178 crossref_primary_10_4161_hv_22877 crossref_primary_10_4161_hv_28857 crossref_primary_10_1586_erv_10_157 crossref_primary_10_1007_s13312_012_0076_7 crossref_primary_10_5812_jjm_11840 crossref_primary_10_1016_j_medmal_2011_03_001 crossref_primary_10_1016_j_vaccine_2012_02_032 crossref_primary_10_1097_INF_0b013e3181fefa1f crossref_primary_10_1097_INF_0b013e3181fefd90 crossref_primary_10_1016_j_jegh_2012_11_004 crossref_primary_10_1016_j_vaccine_2011_01_104 crossref_primary_10_1093_jpids_pix057 crossref_primary_10_1097_MPG_0b013e318282aa12 crossref_primary_10_1016_j_pedneo_2013_05_008 crossref_primary_10_1016_j_vaccine_2011_12_002 crossref_primary_10_1097_INF_0b013e3181fefc68 crossref_primary_10_1016_j_vaccine_2012_05_084 crossref_primary_10_4161_hv_7_5_14620 crossref_primary_10_4236_ojped_2014_44040 crossref_primary_10_1016_j_vaccine_2011_04_087 crossref_primary_10_1016_j_vaccine_2016_10_025 crossref_primary_10_1542_peds_2011_2537 crossref_primary_10_1016_j_vaccine_2010_11_028 crossref_primary_10_1002_bdr2_1674 crossref_primary_10_3928_19382359_20200416_01 crossref_primary_10_3389_fmicb_2022_951716 crossref_primary_10_1371_journal_pone_0067763 crossref_primary_10_2471_BLT_13_125286 crossref_primary_10_1186_1741_7015_9_84 crossref_primary_10_1542_hpeds_2013_0064 crossref_primary_10_1185_03007995_2011_555757 crossref_primary_10_1586_eri_12_39 crossref_primary_10_1016_j_vaccine_2011_08_110 crossref_primary_10_2222_jsv_67_99 crossref_primary_10_1093_infdis_jis314 crossref_primary_10_4161_hv_24831 crossref_primary_10_1097_INF_0b013e3181fefdc0 |
ContentType | Journal Article |
Copyright | 2010 Infectious Diseases Society of America 2010 by the Infectious Diseases Society of America 2010 |
Copyright_xml | – notice: 2010 Infectious Diseases Society of America – notice: 2010 by the Infectious Diseases Society of America 2010 |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1086/652403 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1537-6613 |
EndPage | 1624 |
ExternalDocumentID | 20402596 10_1086_652403 10.1086/652403 27822342 ark_67375_HXZ_QQNBXDVW_D |
Genre | Research Support, U.S. Gov't, P.H.S Comparative Study Journal Article Research Support, N.I.H., Extramural |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GroupedDBID | --- -DZ -~X ..I .2P .I3 .XZ .ZR 08P 0R~ 123 1TH 29K 2AX 2WC 36B 4.4 48X 53G 5GY 5RE 5VS 5WD 70D 85S AABZA AACGO AACZT AAHBH AAHTB AAJKP AAJQQ AAMVS AANCE AAOGV AAPNW AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP AAWTL ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNHQ ABNKS ABOCM ABPEJ ABPLY ABPPZ ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ABZBJ ACGFO ACGFS ACGOD ACHIC ACPRK ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFXAL AFYAG AGINJ AGKEF AGORE AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQVQM ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BR6 BSCLL BTRTY BVRKM C45 CDBKE CS3 CZ4 D-I DAKXR DCCCD DIK DILTD DU5 D~K EBS ECGQY EE~ EJD EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX IPSME J21 JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B LSO LU7 MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TR2 W2D W8F WH7 X7H YAYTL YKOAZ YXANX ~91 AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 .55 .GJ 1KJ 3O- 41~ AAFWJ AAPGJ AAWDT AAYXX ABDPE ABSMQ ACFRR ACPQN ACUTJ ACVCV ACZBC ADMTO AEKPW AFFQV AFHKK AFQQW AFSHK AGKRT AGMDO AHGBF AI. AJDVS APJGH AQDSO AQKUS AVNTJ BZKNY CITATION EIHJH HQ3 HTVGU J5H MBLQV MVM NEJ OBFPC O~Y P0- TMA VH1 X7M Y6R ZE2 ZGI ZXP CGR CUY CVF ECM EIF NPM VXZ YIF 7X8 |
ID | FETCH-LOGICAL-c462t-7cd2716757217cb5574995baf6f15a10c6ba0c64542e716167f1cae01bf17bd13 |
ISSN | 0022-1899 1537-6613 |
IngestDate | Thu Jul 10 23:59:23 EDT 2025 Wed Feb 19 01:52:50 EST 2025 Thu Apr 24 22:57:27 EDT 2025 Tue Jul 01 03:24:18 EDT 2025 Wed Sep 11 04:51:08 EDT 2024 Fri Jun 20 02:31:42 EDT 2025 Tue Aug 05 16:48:53 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c462t-7cd2716757217cb5574995baf6f15a10c6ba0c64542e716167f1cae01bf17bd13 |
Notes | istex:81DCC38C35CC978FEEC60FC962BBD89D41D44167 ark:/67375/HXZ-QQNBXDVW-D ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | https://academic.oup.com/jid/article-pdf/201/11/1617/18059568/201-11-1617.pdf |
PMID | 20402596 |
PQID | 733933116 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_733933116 pubmed_primary_20402596 crossref_primary_10_1086_652403 crossref_citationtrail_10_1086_652403 oup_primary_10_1086_652403 jstor_primary_27822342 istex_primary_ark_67375_HXZ_QQNBXDVW_D |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-06-01 20100601 2010-06-00 2010-Jun-01 |
PublicationDateYYYYMMDD | 2010-06-01 |
PublicationDate_xml | – month: 6 year: 2010 text: 20100601 day: 1 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of infectious diseases |
PublicationTitleAbbrev | The Journal of Infectious Diseases |
PublicationTitleAlternate | The Journal of Infectious Diseases |
PublicationYear | 2010 |
Publisher | The University of Chicago Press University of Chicago Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
References | 21878426 - J Infect Dis. 2011 Oct 1;204(7):975-7 20402594 - J Infect Dis. 2010 Jun 1;201(11):1607-10 |
References_xml | – reference: 21878426 - J Infect Dis. 2011 Oct 1;204(7):975-7 – reference: 20402594 - J Infect Dis. 2010 Jun 1;201(11):1607-10 |
SSID | ssj0004367 |
Score | 2.4239788 |
Snippet | Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute... Background. In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute... In 2006, RotaTeq (RV5) was recommended for routine vaccination of United States (US) infants. We compared hospitalization rates for acute gastroenteritis among... |
SourceID | proquest pubmed crossref oup jstor istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1617 |
SubjectTerms | Age groups Child, Preschool Children Gastroenteritis Gastroenteritis - epidemiology Gastroenteritis - prevention & control Health care costs Hospitalization Hospitalization - statistics & numerical data Hospitalization rates Humans Infant Infant, Newborn Male Preventive medicine Rotavirus Rotavirus Vaccines - immunology Surveillance United States - epidemiology Vaccination Vaccines, Attenuated - immunology VIRUSES |
Title | Reduction in Acute Gastroenteritis Hospitalizations among US Children After Introduction of Rotavirus Vaccine: Analysis of Hospital Discharge Data from 18 US States |
URI | https://api.istex.fr/ark:/67375/HXZ-QQNBXDVW-D/fulltext.pdf https://www.jstor.org/stable/27822342 https://www.ncbi.nlm.nih.gov/pubmed/20402596 https://www.proquest.com/docview/733933116 |
Volume | 201 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJhAvCAaDjpsfgJcqqE7ipOUNdqFC29BYCxUvkZ06UDGlKE0m4PfwE_iBnONLEroiLi9RlTjHUc8X-zj-vnMIeSQhymVKpl7fVzMvVIp7AxkJzw_jmLGZkpKjdvjoOBpNwldTPu10frRYS1Upn6bf1upK_sercA78iirZf_BsbRROwG_wLxzBw3D8Kx-_wbyrjq0oUtzy_yCWZbHARJs6W1Hvo60L4uSWtrrQ5LSRcZsy4XOkrDtzEEEWi1Kcz4tq2TsXKe6-a1l0K4WJs4x7PDrfkuoh3dQIVtgAu9BqpWU7_m2UaDZZhaGCQS92p6gO8XehkamULAp4oiaXJJbntOrFM1EBvNufY2veMRbwrfA_aAE3LxsGiVY9tj954G69o2bVo3TsQWBhRka15pwd2v3mrsrpW-xIjeu6tVNIX-9oRRwTFTaTpCMGHL9ODiaHh8l4fzq-RDZ9WJxg3YyX04ZYFAa6bnH9QK2KVsbqLyHQJr7NXxwbdkVmeWG1o6Oe8XVyzbqKPjfYu0E6Kt8il00B069b5MqRpWbcJN9rMNJ5TjUY6QoY6SoYqQYjnZxSB0aqwUjbYKSLjNZgpBaMz6iDIl52dmkNRYpQpAhFygbYgYHiLTI52B_vjjxbAsRLw8gvvTid-bCij3kMS-dUch7DCp1LkUUZ44L100gKOIQ89BW0g5YZS4XqM5mxWM5YsE028kWu7hB4fjADg1E4Q90NJiaMRMayoQqZ7MOg1CWPnVeS1ObHxzItZ4nmaQyixHivSx7W7T6bjDAXWjzRTq0vi-IT8idjnoym75OTk-MX072375K9LtnWXq8b-hivB6HfJTsAg9-apw4dCcwFuMEncgVvahIHwTAIGIu65LZBTWMZJmufD6OdP998l1xtXrp7ZKMsKnUfIu9SPtBA_wkfTuCP |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+in+acute+gastroenteritis+hospitalizations+among+US+children+after+introduction+of+rotavirus+vaccine%3A+analysis+of+hospital+discharge+data+from+18+US+states&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Curns%2C+Aaron+T&rft.au=Steiner%2C+Claudia+A&rft.au=Barrett%2C+Marguerite&rft.au=Hunter%2C+Katherine&rft.date=2010-06-01&rft.issn=1537-6613&rft.eissn=1537-6613&rft.volume=201&rft.issue=11&rft.spage=1617&rft_id=info:doi/10.1086%2F652403&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon |